The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some findings from the final analysis of the Phase II CLL2-GiVe trial (NCT02758665), which is evaluating the combination of ibrutinib, venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia (CLL) with TP53 aberration. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.
